There is increasing awareness of the immunologic roles of liver mononuclear populations, including myeloid-derived suppressor cells (MDSCs). We took advantage of a large well-defined cohort of 148 patients with liver inflammation and 45 healthy controls to focus on the qualitative and quantitative characteristics of MDSCs. We investigated the frequency, phenotype, and functional capacities of MDSCs by using peripheral blood MDSCs in a cohort of 55 patients with primary biliary cholangitis (PBC), 40 with autoimmune hepatitis, 39 with chronic hepatitis B, 14 with nonalcoholic fatty liver disease, and 45 healthy controls. This was followed by a liver-targeted determination in 27 patients with PBC, 27 with autoimmune hepatitis, 20 with chronic hepatitis B, 14 with nonalcoholic fatty liver disease, and 6 controls. We then focused on mechanisms of this expansion with PBC as an example, using both ursodeoxycholic acid-naive and treated patients. HLA-DR 2/low CD33 1
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There is increasing awareness of the immunologic roles of liver mononuclear populations, including myeloid-derived suppressor cells (MDSCs). We took advantage of a large well-defined cohort of 148 patients with liver inflammation and 45 healthy controls to focus on the qualitative and quantitative characteristics of MDSCs. We investigated the frequency, phenotype, and functional capacities of MDSCs by using peripheral blood MDSCs in a cohort of 55 patients with primary biliary cholangitis (PBC), 40 with autoimmune hepatitis, 39 with chronic hepatitis B, 14 with nonalcoholic fatty liver disease, and 45 healthy controls. This was followed by a liver-targeted determination in 27 patients with PBC, 27 with autoimmune hepatitis, 20 with chronic hepatitis B, 14 with nonalcoholic fatty liver disease, and 6 controls. We then focused on mechanisms of this expansion with PBC as an example, using both ursodeoxycholic acid-naive and treated patients. HLA-DR 2/low CD33 1
CD11b
1 CD14 1 CD15 2 monocytic MDSCs were elevated in diseases characterized by liver inflammation compared to healthy controls. Using PBC as a focus, there was a significant correlation between levels of circulating MDSCs and disease-related biochemical markers (alkaline phosphatase, total bilirubin). We found higher amounts of MDSCs in patients with PBC who were responsive to ursodeoxycholic acid. MDSCs from PBC were found to manifest a potent immunosuppressive function. There was a significant correlation in the accumulation of hepatic MDSCs in the inflamed lesions of PBC with histologic changes, such as fibrosis. We also found that cysteine-rich protein 61 (CCN1), a highly expressed protein in impaired cholangiocytes and hepatocytes, contributes to MDSC expansion and MDSC inducible nitric oxide synthase-associated immune suppression. Conclusion: CCN1 modulates expansion and a suppressive function of MDSCs. Our data highlight the potential functions of CCN1 on MDSCs and suggest therapeutic implications in inflammatory liver diseases. (HEPATOLOGY 2018;67:232-246).
C ellular and molecular dissections of liverspecific immune responses have disclosed sophisticated and often heterogeneous populations of regulatory cells that have the potential to modulate inflammation; these regulatory cells include myeloid-derived suppressor cells (MDSCs). (1, 2) MDSCs are a recently identified heterogeneous cell population with a remarkable regulatory function. (3) In humans, MDSCs have been characterized on the basis of an "immature" phenotype by using the markers CD33 and CD11b and lack expression or have very low levels of the mature myeloid marker human leukocyte antigen-antigen D related (HLA-DR). (4) More specifically, there are three major subpopulations of human MDSCs: 1) the monocytic phenotype (HLA-DR 2/low CD33 
CD15
2 ). (5) The functionality of MDSCs has been primarily based on the suppression of T-cell proliferation by inducible enzymes, such as nitric oxide synthase 2/inducible nitric oxide synthase (iNOS), (6, 7) and the majority of studies involve murine models. (8, 9) Of note, the liver is a preferential site for MDSC accumulation. (10) Our group has previously identified an MDSC population with a predominant monocytic phenotype, (11) and we have hypothesized that such cells, induced by chronic inflammation, serve a beneficial role by limiting T-cell-mediated inflammation. Despite the major efforts in dissecting the genetic basis of and the abnormal serologic and cellular response in both human and murine models of immune-mediated hepatobiliary diseases, (12) (13) (14) there remains a void in defining the role of cellular elements in the critical inflammatory response and especially in recognizing mononuclear subpopulations that potentially have therapeutic implications.
In this respect, we note that during both hepatic and cholangiocyte injury, cysteine-rich protein 61 (CCN1 or Cyr61), a multifunctional factor, (15) (16) (17) has significant effects on hepatic pathogenesis, such as biliary repair, fibrosis resolution, and cancer suppression. CCN1 acts primarily through direct binding to distinct integrin receptors in a cell-type-specific manner to regulate diverse cellular responses. (18) In particular, integrin a M b 2 has proved to be a major adhesion receptor on activated monocytes mediating the adhesion event for CCN1. (19) Given the reparative role of CCN1 in hepatobiliary injury, we first defined the MDSC population in a variety of inflammatory liver diseases; then using PBC as a prototypic process, we focused on mechanisms and the issue of whether there is a correlation between CCN1 and MDSCs. We report herein that MDSCs are expanded in a broad panel of inflammatory liver diseases. Importantly in PBC, severity correlates with the frequency of circulating MDSCs, which are expanded by CCN1, a highly expressed protein in impaired cholangiocytes and hepatocytes, contributing to iNOS-associated immune suppression. Our data suggest that further studies of these unique cells address potential therapeutic implications.
Materials and Methods

PATIENT POPULATION AND STUDY DESIGN
A total of 193 subjects were enrolled in this study (Supporting Table S1 ), and in all cases the diagnosis was based on international criteria, including 55 subjects with PBC, (20) 40 with autoimmune hepatitis (AIH), (21) 39 with chronic hepatitis B (CHB), (22) 14 with nonalcoholic fatty liver disease (NAFLD), (23) (24) All patients with PBC were followed for a period of 15 months and were defined as either UDCA responders or nonresponders. Responders had to fulfill all of the Paris I criteria. Overall, based on this definition, our study included 24/37 UDCA responders and 13/37 nonresponders within the treatment-naive group. In patients already receiving UDCA, there were 12/18 responders and 6/18 nonresponders that were included within the data analysis.
In addition to the serially followed 193 subjects, paraffin-embedded liver tissues were studied, derived from ultrasound-guided needle liver biopsies from 27 patients with PBC, 27 with AIH, 20 with CHB, 14 with NAFLD, and 6 controls. Sections were stained with either hematoxylin and eosin or Masson stains and independently examined by blinded reviewers. Inflammatory degree and fibrotic stages were graded according to the Scheuer scoring system. (25) The six healthy liver tissues (control) were collected from donors whose livers were subsequently used for liver transplantation. All individuals provided written informed consent, and the protocol was approved by the Shanghai Jiao Tong University Ethics Committee. 
IMMUNOPHENOTYPIC ANALYSIS BY FLOW CYTOMETRY
IN VITRO GENERATION OF HUMAN MDSCs
MDSC induction in vitro was quantitated as described. (26) Briefly, human peripheral blood mononuclear cells (PBMCs) were isolated from healthy volunteers by differential density gradient separation. PBMCs were cultured in T-25 flasks at 5 3 10 5 cells/mL in complete medium (Roswell Park Memorial Institute 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 10 mM 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid, 1 mM penicillin-streptomycin, and 50 mM 2-mercaptoethanol) for 5 days, supplemented with cytokines as indicated, including granulocyte-macrophage colony stimulating factor (GM-CSF; 10 ng/mL; R&D Systems), interleukin-6 (IL-6; 10 ng/mL; R&D Systems), and CCN1 (500 ng/ mL; R&D Systems). GM-CSF was added to the mixtures of cytokines to support cell viability. (27) PBMCs cultured in complete medium alone were run in parallel as a control. Cultures were run in duplicate, and medium and cytokines were refreshed every 2-3 days. In the experiments exploring mechanisms, cells were precultured with neutralizing anti-integrin a M b 2 (5 lg/mL; BD Pharmingen) or isotype antibody (5 lg/mL; BD Pharmingen), (15) and signal transducers and activator of transcription 3 (STAT3) inhibitor STATIC (2.5-5 lmol/L; Selleckchem) for 1 hour before stimulation with the cytokine mixture above. After 5 days, all cells were collected from the PBMC cultures. Adherent cells were removed using the nonprotease cell detachment solution Detachin (Genlantis, San Diego, CA). Cells were used for further experiments on characterization of MDSCs, including immunophenotypic analysis by flow cytometry, suppression assay (similar to the method described above), and morphology analysis (WrightGiemsa staining of cytospin cell preparations). (11) For identification of MDSCs with the potential to produce ZHANG, LIAN, ET AL.
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NO, cells were stained with 4-amino-5-methylamino-2 0 ,7 0 -difluorofluoresce in diacetate (DAF-FM-DA), a fluorescent indicator for NO and its metabolites (Invitrogen, Carlsbad, CA), (28) together with the antibodies above. To determine the roles of iNOS or O 2 2 as modulators of T-cell proliferation, 1400W (hydrochloride) (500 nmol/L; Cayman Chemical Co.) or superoxide dismutase (1,000 U/mL; Sigma) was added at the start of the cultures in the MDSC-suppression assay.
STATISTICAL ANALYSIS
All continuous variables are expressed as median (ranges) for the quantitative variables and are presented in Supporting Tables S1 and S2. The Mann-Whitney U test was used to evaluate differences in continuous variables. Dichotomous variables were compared using Pearson 0 s chi-square test. Correlations were determined using Spearman 0 s correlation coefficient. Cumulative biochemical remission rates were estimated by Kaplan-Meier analysis. All analyses were two-tailed and performed using Prism software, version 6.0 (GraphPad Software, Inc., La Jolla, CA).
Results
PERIPHERAL BLOOD ANALYSIS OF MDSCs
There was a significant accumulation of HLA-DR 2/low CD33 1 CD11b 1 cells in the monocytic population in all liver inflammatory diseases compared to controls ( Fig. 1A-C) . Moreover, further analysis using a combination of the monocytic subset marker CD14 and the granulocytic subset marker CD15 indicated that the predominant MDSC cell type in PBC or AIH was HLA-DR 2/low CD33 1C; Supporting Fig. S1B ).
ELEVATED MDSCs IN PBC CORRELATE WITH DISEASE ACTIVITY
There were no sex differences in either the proportion or cell number of circulating MDSCs in any cohort (PBC, AIH, CHB, NAFLD, or HC). To evaluate the clinical significance of the HLA-DR 2/low-
2 MDSCs in PBC, we analyzed the data based on clinical features. There were no differences in data based on antimitochondrial antibody status (data not shown), but there was a correlation between the percentage of circulating HLA-
2 MDSCs and PBC-related biochemical parameters (including ALP, r 5 0.3476, P < 0.05; total bilirubin, r 5 0.3060, P < 0.01) (Fig. 1D,E) . Positive correlations were also observed between the number of HLA-
2 MDSCs and biochemical markers (Supporting Fig. S1C,D) . In contrast, there was no statistical correlation between the frequencies of circulating MDSCs and cglutamyltransferase, AST, alanine aminotransferase, or immunoglobulin M levels (data not shown). We also explored the clinical significance of circulating MDSCs in other liver inflammatory diseases. In AIH and CHB, levels of HLA-DR 2/low CD33
2 MDSCs were positively correlated with biochemical parameters, such as alanine aminotransferase and AST (Supporting Fig. S1E,F) . However, no correlation was found between levels of HLA-
2 MDSCs and biochemical parameters in patients with NAFLD.
HIGHER LEVELS OF MDSCs ARE ASSOCIATED WITH A BETTER BIOCHEMICAL RESPONSE TO UDCA IN PBC
We stratified the PBC cohort into those who had received UDCA treatment and those who were treatment naive at the time of sampling and then compared the profiles of patients who were responsive or nonresponsive to UDCA. Interestingly, patients who responded to UDCA had significantly higher levels, percentages, and cell numbers of HLA-DR 2/low-
CD15
2 MDSCs compared to those who were nonresponders ( Fig. 2A; Supporting  Fig. S2A) .
Based on the median values of HLA-DR 2/low-
2 MDSC density (percentage or cell number), we next divided treatment-naive patients into "low" and "high" groups.
There was 1 year of clinical follow-up data on this cohort, and we noted a significant increase in the numbers of UDCA responders at 1 year in the MDSC high group compared to the MDSC low group (P < 0.05). A similar trend was noted between the MDSC high group and MDSC low group divided by the percentage of MDSCs (P < 0.05) (Supporting Table S3 ). The patients were followed every 3 months during the first year of UDCA treatment. After 3, 6, 9, 12, and 15 months of treatment, we evaluated their biochemical response to UDCA. When MDSC levels (both percentage and cell number) were dichotomized at the median, there were significantly better cumulative biochemical remission rates in patients with high MDSC levels compared with those with low MDSC levels (P < 0.05 for percentage; P < 0.05 for cell number) ( Fig.  2B; Supporting Fig. S2B ). Intriguingly, in the longitudinal study, the levels (percentage or cell number) of HLA-DR 2/low CD33
MDSCs significantly increased in the early responder cohort at the sixth month of UDCA therapy (n 5 10) ( Fig. 2C; Supporting Fig. S2C ).
SUPPRESSOR FUNCTION OF MDSCs IN PBC
To investigate the functional characteristics of MDSCs, we employed the NO indicator dye DAF-FM-DA and a selection of cell-surface markers (HLA-DR 2/low CD33 1 CD11b 1 ) to identify NOproducing MDSCs. Increased levels of NO and its metabolites were detected in MDSCs from PBC compared to HCs (P < 0.0001) (Fig. 3A) . Furthermore, to study the suppressor function of MDSCs, we added the sorted HLA-DR 2/low CD33 1
CD11b
1 MDSCs to CD3/CD28-stimulated autologous T cells at different ratios and then analyzed proliferation. Notably, MDSCs from patients with PBC had more immunosuppressive activity on autologous T-cell responses than HCs (Fig. 3B,C) . We further analyzed the culture medium to assess for relevant secreted nitrite (a stable metabolite of NO). Elevated production of nitrite was observed in the PBC-MDSC group (P < 0.01 for 1:4; P < 0.01 for 1:10) and the HC group (P < 0.01 for 1:4). Of interest, the concentration of nitrite from the PBC-MDSC group was significantly higher than that of the HCs (P < 0.01) (Fig. 3D) .
However, other molecules, such as S100A8/A9 and transforming growth factor-b, were not implicated in MDSC-mediated suppression from the PBC or HC groups (Supporting Fig. S3A,B) . Interestingly, T-cell proliferation from PBC or the HCs could be improved following removal of the added MDSCs (Fig. 3E) . 
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ENRICHMENT OF MDSCs IN PBC LIVER
Of note, patients with PBC demonstrated significantly increased levels of CD33
1 CD11b 1 cells compared to HCs, and we highlight that CD33 1 CD11b 1 cells also accumulated in the liver of AIH, CHB, NAFLD, and HCs, but the numbers in PBC were significantly higher (PBC versus HC, P < 0.0001; PBC versus AIH, P < 0.05; PBC versus CHB, P < 0.05; PBC versus NAFLD, P < 0.05). Confocal staining demonstrated that CD33 and CD11b were colocalizedin PBC liver (Fig. 4A) . As CD33 is a better surrogate for the monocytic MDSC marker than CD11b, we 
CD33
1 cells in PBC liver (Fig. 4B) . Moreover, we then used immunohistochemical staining to better observe the expression and distribution of MDSCs in liver. Immunohistochemical staining of CD33 in liver was primarily located on the membranous cell surface (Fig. 4C) . In addition, the majority of CD33 1 cells were scattered within inflamed portal tracts. While limited CD33
1 cells were found in the livers of HCs, we observed significantly increased numbers of CD33 1 cells in the liver of PBC (P < 0.01). Furthermore, the numbers of CD33 1 cells were positively correlated with inflammation (r 5 0.5492; P < 0.01) and hepatic fibrosis stages (r 5 0.6829; P < 0.01) in PBC (Fig. 4D) . Immunohistochemical staining of CD11b in patients with PBC was particularly bright in myeloid cells compared to relatively faint staining in HC samples. CD11b 1 cells were generally aggregated in inflamed portal tracts (Fig. 4E) . Likewise, there were significantly increased CD11b 1 cells in PBC compared to HCs (P < 0.01). Moreover, the numbers of CD11b 1 cells were positively correlated with inflammation (r 5 0.6403; P < 0.01) and fibrosis (r 5 0.4052; P < 0.05) of PBC (Fig. 4F) .
INFLUENCE OF CCN1 ON MDSCs
Previous data revealed that accumulation of MDSCs requires two sets of signals. The first of these signals is growth factors, i.e., GM-CSF, which supports the expansion of immature myeloid cells. More importantly, a second signal provides myeloid cells with a suppressive phenotype that defines this cell type. CCN1 is a highly expressed matricellular protein in cholestatic liver diseases. In PBC, CCN1 is typically located in damaged bile ducts, hepatocytes, and some other inflammatory cells in the portal tract (Fig.  5A,B) . Notably, CCN1 is highly elevated in PBC liver while nearly undetectable in HCs (P < 0.01). We also noted elevated expression of CCN1 in AIH (P < 0.01), CHB (P < 0.05), and NAFLD (P < 0.05) liver (Supporting Fig. S4A) . Strikingly, the expression of CCN1 was positively correlated with the numbers of CD33 1 cells (r 5 0.4598; P < 0.05) and CD11b 1 cells (r 5 0.7037; P < 0.01) in PBC liver (Fig. 5C ).
Significantly elevated levels of CCN1 were also found in PBC liver and HCs by enzyme-linked immunosorbent assay (ELISA) (Fig. 5D) . We further used ELISA to determine the expression of CCN1 in plasma of our cohort. Concordant with an elevated expression in liver, we also noted a significantly higher circulating expression of CCN1 in PBC than in HCs (P < 0.01) (Fig. 5E ). The plasma levels of CCN1 were positively correlated with levels of circulating HLA-DR 2/low CD33 1 CD11b 1 MDSCs (percentage, r 5 0.4086, P < 0.01; cell number, r 5 0.4643, P < 0.01) (Fig. 5 E; Supporting Fig. S4B) . Similarly, the plasma levels of CCN1 were also positively correlated with the level of circulating monocytic MDSCs (percentage, r 5 0.3800, P < 0.01; cell number, r 5 0.4046, P < 0.01) ( Fig. 5E; Supporting Fig. S4C) . We also noted elevated plasma levels of CCN1 in AIH (P < 0.01) and CHB (P < 0.05) (Supporting Fig. S4D ). To test whether CCN1 can directly expand MDSCs, we next stimulated human PBMC with CCN1 with/without GM-CSF. Cytokine mixtures (GM-CSF 1 IL-6) were used as positive controls. (26) Strikingly, together with the first growth signal-GM-CSF, CCN1 induced both the percentage and cell number of HLA-DR 2/low CD33 1
CD11b
1 MDSCs in vitro (percentage, P < 0.01; cell number, P < 0.01) ( Fig. 5F; Supporting Fig. S4E) . Moreover, the addition of CCN1 to IL-6 together with GM-CSF demonstrated enhancement in inducing MDSCs. Indeed, the induction effect of CCN1 was equivalent to IL-6. For example, MDSC expansion by CCN1 increased significantly by day 3 and peaked at day 5 at the optimal concentration of 500 ng/mL (Supporting Fig.  S5A,B) . Immunophenotypic analysis of these GM-CSF 1 CCN1-induced HLA-DR 
CD33
1 cells isolated from the GM-CSF 1 CCN1 induction group were composed of large mononuclear cells (Supporting Fig. S6A,B) .
EXPANSION OF FUNCTIONAL MDSCs WITH iNOS ACTIVITY BY CCN1 IS MEDIATED BY INTEGRIN RECEPTOR a M b 2 AND INCREASED PHOSPHORYLATION OF STAT3
To investigate whether the effects of CCN1 induction on MDSCs were mediated through STAT3, we monitored CCN1-induced STAT3 phosphorylation (pSTAT3) in MDSCs; a significant increase in pSTAT3 mean fluorescence intensity was observed in PBMCs treated with CCN1, similar to the positive control (GM-CSF 1 IL-6) (Fig. 6A) . Moreover, when the STAT3 inhibitor STATIC was added in the presence of CCN1, the expansion of MDSCs was completely abrogated ( Fig. 6B; Supporting Fig. S7A ). Further, when integrin a M b 2 was blocked with neutralizing antibody, the expansion of MDSCs by CCN1 was reduced ( Fig. 6C; Supporting Fig. S7B) . Neutralization of integrin a M b 2 abrogated pSTAT3 expression by GM-CSF 1 CCN1 stimulation compared with cells exposed to the isotype antibody (Supporting Fig. S8 ). To assess whether these CCN1-expanded MDSCs were functional, we sorted GM-CSF 1 CCN1-induced HLA-DR 2/low CD11b 1 CD33 1 cells and cocultured these cells with allogeneic proliferating pan-T cells. Strikingly, GM-CSF 1 CCN1-induced MDSCs suppressed pan-T-cell proliferation (Fig. 6D) . The majority of CCN1-expanded HLA-DR 2/low CD11b 1 CD33 1 cells had high NO activity compared to baseline and other cytokine treatment controls (Supporting Fig. S9 ). We next quantified NO metabolites in the culture medium of the aforementioned CCN1-expanded MDSCs by ELISA. CCN1-expanded MDSCs exhibited strikingly high levels of nitrite (Fig. 6E) . Additionally, to explore the relative contribution of iNOS on the function of CCN1-expanded MDSCs, iNOS inhibitor 1400W (hydrochloride) and reactive oxygen species (ROS) inhibitor superoxide dismutase (as a negative control) were added to MDSCs and the pan-T-cell coculture assay. Intriguingly, T-cell proliferation was restored in the CCN1-expanded MDSC group following neutralization of iNOS but not in the ROS-expanded MDSC group (Fig. 6F) . Thus, CCN1 mediates the expansion of functional MDSCs with elevated iNOS activity by binding to its receptor integrin a M b 2 , which leads to increased pSTAT3.
Discussion
There have been significant advances in cellular immunology and especially in defining unique immunosuppresive subpopulations that were unrecognized until relatively recently. This is particularly true of the liver, in which the local microenvironment clearly plays a critical role not only in breach of tolerance but also in the effector mechanisms that propagate inflammation and ultimately fibrosis. (29) (30) (31) PBC illustrates this paradigm in which it is particularly important to dissect the role of immunosuppressive subpopulations, including MDSCs. Until relatively recently, the study of MDSCs had been limited to neoplasia. (32) In contrast, it has been difficult to study MDSCs in humans with autoimmunity because of the number of available cells, the difficulty in finding patients with defined stages of disease activity, and often the relative lack of target tissue, i.e., liver. In our study, we have defined the circulating liver-infiltrating MDSCs in liver inflammation with several noteworthy observations. First, we demonstrated that HLA-DR 2/low CD33 (Fig. 7) .
It is important to note that there remains debate regarding the differential function of MDSC subsets. For example, monocytic and granulocytic populations are reported to exhibit immune suppression in a disease-and tissue site-specific fashion. (33, 34) Monocytic MDSCs increase with inflammation and are characterized by high levels of NO and low levels of ROS production, whereas granulocytic MDSCs produce a high amount of ROS and insignificant levels of NO. (35, 36) Of interest, our data on expansion of human monocytic MDSCs during cholangitis is in agreement with our previous data in an experimental murine system in which elevated numbers of monocytic MDSCs were found with increased inflammatory responses. (11) The mechanisms that lead to changing liver immunoregulatory populations during inflammation are influenced by the local microenvironment, including cytokines, vascular growth factors, and the influence of the major histocompatibility complex. (37) (38) (39) These factors are similar to the induction of expansion and activation of MDSCs. Strikingly, the level of MDSCs was positively correlated with clinical biochemical markers (ALP and total bilirubin) in PBC. Further, treatment responders reflected significantly higher levels of circulating MDSCs before initialization of treatment than nonresponders, and there were more biochemical remission rates in patients with increased numbers of MDSCs. Taken together, these data suggest a counter-regulatory effect of MDSCs and provide a potential marker for prediction of treatment response. Concordant with these findings, we also noted a significant increase in levels of MDSCs in patients with PBC that responded well to UDCA. This observation is important as it raises the possibility of successful antigen-specific immune regulation. (40) Indeed, in our previous study we demonstrated that adoptive transfer of MDSCs in immune-mediated liver injury was followed by a significant reduction in disease severity in recipient mice. (11) These data are also consistent with other models in which MDSCs have been proposed as immunotherapeutic effectors for type I diabetes, (41) multiple sclerosis, (42) and rheumatoid arthritis. (43) CCN1 has been known to orchestrate and induce a ductular reaction during cholestatic diseases, such as PBC. (44) Moreover, CCN1 can bind to the monocyte/ macrophage surface receptor-integrin a M b 2 to induce activation. (18) We hypothesized that CCN1 produced during cholangiopathies may drive the expansion of MDSCs, and we observed that CCN1 can lead to the expansion of MDSCs by acting on integrin a M b 2 . Our results reveal a pivotal functional role of CD11b for MDSC expansion. Further, we demonstrated that STAT3 activation is involved in CCN1-mediated MDSC expansion. There is consensus that STAT3 may be a critical transcription factor for the expansion of MDSCs. (3) More importantly, MDSCs expanded by CCN1 stimulation are functional, up-regulating iNOS expression and hence promoting the suppressive activity of inhibiting T-cell proliferation. CCN1 is emerging as a critical regulator of inflammation and injury repair. We report herein an elevated expression of CCN1 in PBC, AIH, and CHB. Liver fibrosis is a wound-healing response to various chronic liver injuries, regardless of the underlying etiology. (16) Therefore, we hypothesize that our proposed mechanism of CCN1 may be a generic response in liver fibrosis.
Aside from its essential roles in regulating MDSCs, other pathways may be involved in CCN1 interactions and their downstream effects, including the angiogenic and proliferative potentials of CCN1. Indeed, CCN1 is a direct target of Wnt/b-catenin signaling and plays an important role in the progression of hepatocellular carcinoma (45) ; it also induces cholangiocyte proliferation through integrina v b 5 /a v b 3 -mediated nuclear factor kappa B activation. (44) We suggest that further study of CCN1 may lead to a potential therapeutic role in hepatobiliary injury repair. Taken together, we propose that functional MDSCs serve as negative regulators of excessive T-cell responses. Previous studies have reported that intravenous murine administration of MDSCs leads to preferential accumulation of MDSCs in liver. (10, 11) Such efforts will require strategies to optimize therapeutic effectiveness and limit "off-target" T-cell suppression. (8) We submit that it is likely that all liver inflammatory responses are associated with altered MDSC number and frequency and are not specific to PBC. Successful treatment of autoimmune liver diseases will come with better definitions of not only the specific effector pathways but also their functional ability to interact with specific inflammatory pathways. Our future studies will include the functional significance of MDSC in AIH in particular and likewise in further defining the pathways that modulate MDSC expression and function.
